Alnylam Pharmaceuticals (NASDAQ:ALNY) is a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. The company is a leader in this innovative field, aiming to treat genetic diseases by silencing specific genes. Alnylam's competitors include Ionis Pharmaceuticals and Moderna, which also explore genetic-based therapies.
On February 18, 2025, Kevin Joseph Fitzgerald, Alnylam's Chief Scientific Officer, sold 115 shares of the company's stock at $251.60 each. Despite this sale, Fitzgerald still holds 13,120 shares. This transaction comes after Alnylam's strong fourth-quarter 2024 performance, where earnings and revenues exceeded expectations.
Alnylam reported adjusted earnings of 6 cents per share, surpassing the Zacks Consensus Estimate of a 21-cent loss. This is a significant improvement from the previous year's loss of 77 cents per share. The company's total revenues reached $593.2 million, exceeding the anticipated $570 million, driven by a 30% rise in net product revenues.
The increase in product sales is largely due to strong demand for Amvuttra (vutrisiran), a newly approved drug. This contributed to a 35% year-over-year revenue growth from $439.7 million. Despite these positive results, ALNY's stock is currently priced at $250, reflecting a 2.52% decrease.
ALNY's stock has fluctuated between $249.16 and $259.95 during the trading day. Over the past year, it reached a high of $304.39 and a low of $141.98. With a market capitalization of approximately $32.36 billion, ALNY remains a significant player in the biopharmaceutical industry. Today's trading volume is 880,786 shares.
